SCM
TPTX

Silverarc Capital Management’s Turning Point Therapeutics, Inc. Common Stock TPTX Stock Holding History

Silverarc Capital Management’s Portfolio TPTX Stock Details TPTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-16,741
Closed -$1.58M – 126
2021
Q1 		$1.58M Buy
16,741
+610
+4% +$72.5K 0.86% 43
2020
Q4 		$1.97M Buy
+16,131
New +$1.77M 1.14% 33

Other funds holding TPTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Silverarc Capital Management's TPTX Position: Q2 2021 in Review

Silverarc Capital Management sold out of Turning Point Therapeutics, Inc. Common Stock (TPTX) in Q2 2021, closing a stake of 16,741 shares — an estimated $1.58M sold.

Silverarc Capital Management first reported a position in TPTX in Q4 2020 and held it in 2 quarters. The position peaked at $1.97M in Q4 2020. 190 funds tracked by Wall St. Rank hold TPTX as of Q2 2021.

  • Silverarc Capital Management reported no remaining Turning Point Therapeutics, Inc. Common Stock position as of Q2 2021 after selling out during the quarter.
  • Silverarc Capital Management sold 16,741 Turning Point Therapeutics, Inc. Common Stock shares in Q2 2021, an estimated $1.58M.
  • Silverarc Capital Management first reported a position in Turning Point Therapeutics, Inc. Common Stock in Q4 2020 and held it in 2 quarters.
  • Silverarc Capital Management's Turning Point Therapeutics, Inc. Common Stock position peaked at $1.97M in Q4 2020.
  • 190 funds tracked by Wall St. Rank held Turning Point Therapeutics, Inc. Common Stock as of Q2 2021.

Based on Silverarc Capital Management's 13F filing for Q2 2021, filed 16 Aug 2021.